This presentation provides an overview of an investment opportunity in EcoStim, an oilfield services company. It summarizes EcoStim's plans to refinance and restructure the company through a debt-to-equity conversion, raising $17 million in new capital. This will allow EcoStim to pursue growth in Argentina, where it currently operates, and expand into the US market in Oklahoma in 2017. The presentation outlines EcoStim's technology-driven service offerings and growth strategy, as well as the experience and track record of its management team in previously building and exiting energy companies.
This document is an investor presentation by Pressure BioSciences, Inc. discussing the company's Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PBI has developed instruments and consumables for pressure cycling technology (PCT), which uses alternating cycles of hydrostatic pressure to rapidly and reproducibly lyse cells and tissues to prepare samples for analysis.
- PCT addresses limitations in current sample preparation methods, providing a multi-billion dollar market opportunity. Over 275 PCT systems have been installed worldwide.
- Recent achievements include eliminating debt, releasing a next-generation instrument, collaborating with SCIEX, and expected revenue growth from new products and expanded sales team.
This presentation provides an overview of Interpace Diagnostics Group (IDXG), a commercial company that provides molecular diagnostic tests and pathology services for cancer evaluation. IDXG operates two CLIA-certified labs and has four proprietary molecular diagnostic tests for pancreatic cysts and thyroid nodules that assess cancer risk. The tests have high margins and barriers to entry due to reimbursement and complexity. Recent accomplishments include raising funds, improving financials, expanding insurance coverage and launching international distribution. The molecular diagnostic market is large and growing due to advantages over drug development. IDXG's tests establish new standards in cancer risk assessment for pancreatic cysts and thyroid nodules compared to current guidelines.
Cancer Genetics reported on its Q4 and full year 2016 earnings. Key highlights included 50% revenue growth in 2016 to $27 million, driven by increases in biopharma, clinical, and discovery services. The company realized operational efficiencies through integration of acquisitions, reducing expenses. However, the company reported a net loss of $15.8 million for 2016. In Q4 2016, revenue increased 32% to $7.2 million while expenses decreased, though the company reported a net loss of $2.8 million. Additionally, Cancer Genetics completed a $12 million debt refinancing to repay existing debt and access additional capital.
This presentation provides an overview of NeoGenomics' proposed acquisition of Clarient, which would more than double NeoGenomics' revenue. The strategic rationale is that the combined company would have greater scale and a more balanced oncology product portfolio, allowing it to be a lower-cost provider. It would also gain a larger clinical trials business and enhanced geographic coverage. Synergies of $20-30 million annually are projected from consolidating laboratories, purchasing, cross-selling and other areas. The acquisition supports NeoGenomics' strategy of using M&A to accelerate its vision of becoming a leading cancer testing and information company.
- NeoGenomics is acquiring Clarient, which should more than double NeoGenomics' revenue in 2016.
- The acquisition creates a leading cancer testing and information company with expanded geographic coverage and a more comprehensive product menu.
- Synergies of $20-30 million per year are expected from cost savings and cross-selling opportunities between the two companies.
This presentation by Pressure BioSciences discusses their Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PCT uses ultra-high pressure to break up cell walls and extract biomolecules, achieving better results than mechanical methods.
- The market for biological sample preparation is multi-billion dollars. PCT addresses the need for improved sample prep methods.
- Over 275 PCT systems have been installed at over 150 customer sites. There are over 100 publications highlighting PCT's advantages.
- Recent accomplishments include a co-marketing agreement with SCIEX, a leader in analytical technologies, and sales of their new Barocycler 2320EXTREME system.
Therapix Biosciences is a clinical-stage pharmaceutical company focusing on proprietary synthetic cannabinoid technologies developed in Israel, including novel sublingual and nasal formulations of FDA-approved synthetic THC (dronabinol) to treat conditions like Tourette Syndrome and mild cognitive impairment. The company is repurposing dronabinol for new indications by exploring combination therapies based on the "entourage effect" as well as an "ultra-low dose THC" approach for cognitive deterioration and pre-Alzheimer's disease.
This document is an investor presentation by Pressure BioSciences, Inc. discussing the company's Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PBI has developed instruments and consumables for pressure cycling technology (PCT), which uses alternating cycles of hydrostatic pressure to rapidly and reproducibly lyse cells and tissues to prepare samples for analysis.
- PCT addresses limitations in current sample preparation methods, providing a multi-billion dollar market opportunity. Over 275 PCT systems have been installed worldwide.
- Recent achievements include eliminating debt, releasing a next-generation instrument, collaborating with SCIEX, and expected revenue growth from new products and expanded sales team.
This presentation provides an overview of Interpace Diagnostics Group (IDXG), a commercial company that provides molecular diagnostic tests and pathology services for cancer evaluation. IDXG operates two CLIA-certified labs and has four proprietary molecular diagnostic tests for pancreatic cysts and thyroid nodules that assess cancer risk. The tests have high margins and barriers to entry due to reimbursement and complexity. Recent accomplishments include raising funds, improving financials, expanding insurance coverage and launching international distribution. The molecular diagnostic market is large and growing due to advantages over drug development. IDXG's tests establish new standards in cancer risk assessment for pancreatic cysts and thyroid nodules compared to current guidelines.
Cancer Genetics reported on its Q4 and full year 2016 earnings. Key highlights included 50% revenue growth in 2016 to $27 million, driven by increases in biopharma, clinical, and discovery services. The company realized operational efficiencies through integration of acquisitions, reducing expenses. However, the company reported a net loss of $15.8 million for 2016. In Q4 2016, revenue increased 32% to $7.2 million while expenses decreased, though the company reported a net loss of $2.8 million. Additionally, Cancer Genetics completed a $12 million debt refinancing to repay existing debt and access additional capital.
This presentation provides an overview of NeoGenomics' proposed acquisition of Clarient, which would more than double NeoGenomics' revenue. The strategic rationale is that the combined company would have greater scale and a more balanced oncology product portfolio, allowing it to be a lower-cost provider. It would also gain a larger clinical trials business and enhanced geographic coverage. Synergies of $20-30 million annually are projected from consolidating laboratories, purchasing, cross-selling and other areas. The acquisition supports NeoGenomics' strategy of using M&A to accelerate its vision of becoming a leading cancer testing and information company.
- NeoGenomics is acquiring Clarient, which should more than double NeoGenomics' revenue in 2016.
- The acquisition creates a leading cancer testing and information company with expanded geographic coverage and a more comprehensive product menu.
- Synergies of $20-30 million per year are expected from cost savings and cross-selling opportunities between the two companies.
This presentation by Pressure BioSciences discusses their Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PCT uses ultra-high pressure to break up cell walls and extract biomolecules, achieving better results than mechanical methods.
- The market for biological sample preparation is multi-billion dollars. PCT addresses the need for improved sample prep methods.
- Over 275 PCT systems have been installed at over 150 customer sites. There are over 100 publications highlighting PCT's advantages.
- Recent accomplishments include a co-marketing agreement with SCIEX, a leader in analytical technologies, and sales of their new Barocycler 2320EXTREME system.
Therapix Biosciences is a clinical-stage pharmaceutical company focusing on proprietary synthetic cannabinoid technologies developed in Israel, including novel sublingual and nasal formulations of FDA-approved synthetic THC (dronabinol) to treat conditions like Tourette Syndrome and mild cognitive impairment. The company is repurposing dronabinol for new indications by exploring combination therapies based on the "entourage effect" as well as an "ultra-low dose THC" approach for cognitive deterioration and pre-Alzheimer's disease.
This company presentation provides an overview of a cancer genetic testing services company. Key points include:
- The company has experienced strong and consistent growth in revenue and test volume over the past 10 years through both organic growth and acquisitions.
- It provides a broad menu of genetic and molecular testing services including next generation sequencing and is developing liquid biopsy tests.
- The company has an experienced management team with experience in large reference laboratories. It is focused on innovation, cost management, and expanding its commercial footprint.
- Financial results show increasing margins, productivity, and adjusted EBITDA despite lower average prices per test, demonstrating strong operating leverage as the business scales.
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
This document provides an overview of Toni Rinow's presentation on corporate transactions. It discusses her experience in areas such as mergers and acquisitions, financing, deal sheets, and the global expansion risks associated with acquisitions. Specific examples discussed include acquisitions carried out by JSS Medical Research in Canada, India, Latin America, and Poland to expand their global clinical research presence. The presentation also covers business valuation methods and challenges of integrating acquired companies.
This presentation provides an overview of Scythian Biosciences Inc., a pharmaceutical company developing cannabinoid-based drug therapies for traumatic brain injury (TBI). It discusses the large market opportunity for treating TBI, outlines Scythian's solution to develop drugs that inhibit immune response and inflammation following TBI, and presents the company's preclinical and clinical development timelines and leadership team.
March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast...Hawk Associates, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
The document provides an overview of Coherus BioSciences and their CHS-1701 pegfilgrastim biosimilar program. Key points include:
[1] CHS-1701 has completed a positive pivotal PK/PD study meeting all primary endpoints and demonstrating similar safety to Neulasta.
[2] Coherus has a strategic manufacturing agreement with KBI to support commercial launch and long-term supply of CHS-1701.
[3] The Neulasta market is very large at over $4B annually in the US and concentrated among a small number of buyers, making it well-suited for a biosimilar.
This document provides an overview of Cancer Genetics, Inc. (CGI) and their focus on being an oncology diagnostics partner from bench to bedside. Some key points:
- CGI utilizes targeted acquisitions and collaborations with research institutions to expand their testing capabilities and global footprint.
- They have a proprietary portfolio of over 20 genomic tests and panels focused on cancers like blood cancers, lymphomas, lung cancer, and solid tumors.
- CGI partners with leading biopharma companies, supporting over 120 clinical trials with testing and services. They have contracts with 8 of the top 10 biopharma companies.
Exact Sciences Q4 2015 and Full Year Earnings CallExact Sciences
This document contains the summary of Exact Sciences' Q4 2015 and full year earnings call. It discusses the company's strong growth in 2015 with 104,000 Cologuard tests completed and 600 cancers detected. The company provides guidance of $90-100 million in revenue for 2016 by continuing to expand reimbursement coverage and increase marketing efforts. Exact Sciences also discusses opportunities to drive further growth through a total office sales call strategy and developing new product pipelines to detect other cancers like lung and pancreatic cancer. The presentation emphasizes Cologuard's superior performance, cost-effectiveness, high compliance rate, and patient preference compared to other colon cancer screening options.
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...ANGLE plc
Liquid biopsy from a simple blood test is enabling personalised cancer care. The Parsortix system from ANGLE can harvest cancer cells from blood (liquid biopsy) in a non-invasive and repeatable way. This provides a new approach to obtaining cancer cells for analysis compared to traditional tumour biopsies. Key opinion leaders have evaluated the Parsortix system and found that it captures all types of cancer cells with high purity in an easy to use process, making it well suited for clinical applications in personalised cancer care.
The document discusses Troilus Gold Corp, a mining company advancing the past-producing Troilus gold and copper mine in Quebec, Canada. It provides an overview of the project's geology, history of production, existing infrastructure including roads and power lines, and growth in mineral resources. It also summarizes the company's financial information including market capitalization, institutional shareholders, and cash on hand as it works to restart mining operations at Troilus.
Eco-Stim Energy Solutions (“ESES”, “Eco-Stim”, or “Company”) is an environmentally focused oilfield service and technology company providing proprietary field management technologies, well stimulation, and completion services to oil and gas producers drilling in the rapidly expanding international unconventional shale markets. Eco-Stim’s proprietary methodology and technology offers the potential to decrease the number of stages stimulated in shale plays through a unique process that predicts high-probability production zones while confirming those production zones using the latest generation down-hole diagnostic tools. In addition, Eco-Stim offers its clients completion techniques that can dramatically reduce horsepower requirements, emissions, surface footprint, and water usage. Eco-Stim seeks to deliver well completion services with better technology, better ecology, and significantly improved economics for unconventional oil and gas producers worldwide.
EcoStim provides well stimulation, coiled tubing, and reservoir management services using proprietary technologies. It has positioned 50,000 HHP of equipment in Argentina ahead of increasing shale drilling activity. EcoStim's growth opportunity is attractive due to supply constraints in Argentina and barriers to entry that limit competitors from rapidly expanding capacity. The company has a strong customer base of major oil and gas producers operating in Argentina and is bidding on several new contracts worth over $50 million as customers finalize 2017 budgets. Argentina's shale development is following a similar path as U.S. plays and is expected to rapidly increase horizontal drilling in coming years, providing significant growth potential for EcoStim.
- The company provides well stimulation, coiled tubing, and reservoir management services using proprietary technologies that reduce environmental impact and improve economic performance.
- It has established local operations in Argentina and plans to capitalize on developing the country's large shale resources, which could reduce Argentina's need to import billions in energy annually.
- The management team has experience building profitable energy companies and exiting some for over $4.5 billion total. Major investors include Albright Capital Management, Gilder Gagnon, Bienville Capital, and Hayman Capital.
This corporate presentation discusses the company's plans to capitalize on emerging market developments and increasing demand for unconventional oil and gas solutions in Argentina. It highlights the country's large shale resources, ongoing investments by major oil companies, and an undersupplied market that leaves room for the company to expand its operations across multiple market segments. The presentation also outlines the company's leadership team and track record of success building profitable energy service platforms.
EcoStim is an emerging growth, technology-driven oilfield services company providing well stimulation, coiled tubing, and reservoir management services. It has developed proprietary technologies that reduce environmental impact and improve economic performance. The company is capitalizing on emerging market opportunities in Argentina, which has the 3rd largest shale gas reserves in the world. Argentina currently imports over $6 billion per year of oil and gas, and developing its shale resources could help reduce these imports and bolster its dollar reserves. EcoStim is well positioned for growth as Argentina's new pro-business government has made policy changes to encourage more oil and gas development.
The presentation provides an overview of Asanko Gold's operational performance and plans for 2018. Key points include:
1) Asanko produced 205,047 ounces of gold in 2017 in line with guidance. Optimization efforts have increased processing capacity to 5Mtpa.
2) Production guidance for 2018 is 200,000-220,000 ounces. The first half of 2018 will focus on waste stripping at Nkran, lowering grades and increasing costs.
3) A funding solution is being finalized to defer debt repayments beyond 2019, securing funding for an overland conveyor and development of the Esaase deposit.
4) Optimization plans aim to reduce strip ratios and costs over the expansion
Victory Energy (VYEY) Investor PresentationDerek Gradwell
Victory Energy Corporation is a public oil and gas exploration company focused on development in the Permian Basin. The company owns interests in several producing properties in the basin. Victory plans to deploy $15 million in 2014 for drilling, completions, and acquisitions to increase production and proved reserves. The goal is to achieve over 30 million barrels of proved reserves by year-end and increase revenue to over $1 million. A key focus is the recently acquired 4,050 acre Fairway project, which Victory expects can generate a 60% internal rate of return over three years of planned drilling.
The presentation discusses EcoStim's plans, strategies, and prospects, noting that some statements are forward-looking in nature. It provides an overview of EcoStim's operations in the US and Argentina, including recent contract wins that position it for growth. It highlights EcoStim's debt-free balance sheet, experienced management team, and technologies such as natural gas powered pumping units that reduce costs and emissions.
EcoStim is an oilfield services company providing well stimulation services in the US and Argentina. The presentation highlights:
1) EcoStim has secured multiple new contracts in 2017 anchoring a second crew in the US and a long-term contract in Argentina, positioning it for accelerated growth.
2) EcoStim trades at an attractive valuation compared to peers based on enterprise value per hydraulic horsepower.
3) EcoStim utilizes proprietary downhole diagnostic and predictive technologies to more efficiently target completion stages, reducing costs for customers.
This company presentation provides an overview of a cancer genetic testing services company. Key points include:
- The company has experienced strong and consistent growth in revenue and test volume over the past 10 years through both organic growth and acquisitions.
- It provides a broad menu of genetic and molecular testing services including next generation sequencing and is developing liquid biopsy tests.
- The company has an experienced management team with experience in large reference laboratories. It is focused on innovation, cost management, and expanding its commercial footprint.
- Financial results show increasing margins, productivity, and adjusted EBITDA despite lower average prices per test, demonstrating strong operating leverage as the business scales.
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
This document provides an overview of Toni Rinow's presentation on corporate transactions. It discusses her experience in areas such as mergers and acquisitions, financing, deal sheets, and the global expansion risks associated with acquisitions. Specific examples discussed include acquisitions carried out by JSS Medical Research in Canada, India, Latin America, and Poland to expand their global clinical research presence. The presentation also covers business valuation methods and challenges of integrating acquired companies.
This presentation provides an overview of Scythian Biosciences Inc., a pharmaceutical company developing cannabinoid-based drug therapies for traumatic brain injury (TBI). It discusses the large market opportunity for treating TBI, outlines Scythian's solution to develop drugs that inhibit immune response and inflammation following TBI, and presents the company's preclinical and clinical development timelines and leadership team.
March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast...Hawk Associates, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
The document provides an overview of Coherus BioSciences and their CHS-1701 pegfilgrastim biosimilar program. Key points include:
[1] CHS-1701 has completed a positive pivotal PK/PD study meeting all primary endpoints and demonstrating similar safety to Neulasta.
[2] Coherus has a strategic manufacturing agreement with KBI to support commercial launch and long-term supply of CHS-1701.
[3] The Neulasta market is very large at over $4B annually in the US and concentrated among a small number of buyers, making it well-suited for a biosimilar.
This document provides an overview of Cancer Genetics, Inc. (CGI) and their focus on being an oncology diagnostics partner from bench to bedside. Some key points:
- CGI utilizes targeted acquisitions and collaborations with research institutions to expand their testing capabilities and global footprint.
- They have a proprietary portfolio of over 20 genomic tests and panels focused on cancers like blood cancers, lymphomas, lung cancer, and solid tumors.
- CGI partners with leading biopharma companies, supporting over 120 clinical trials with testing and services. They have contracts with 8 of the top 10 biopharma companies.
Exact Sciences Q4 2015 and Full Year Earnings CallExact Sciences
This document contains the summary of Exact Sciences' Q4 2015 and full year earnings call. It discusses the company's strong growth in 2015 with 104,000 Cologuard tests completed and 600 cancers detected. The company provides guidance of $90-100 million in revenue for 2016 by continuing to expand reimbursement coverage and increase marketing efforts. Exact Sciences also discusses opportunities to drive further growth through a total office sales call strategy and developing new product pipelines to detect other cancers like lung and pancreatic cancer. The presentation emphasizes Cologuard's superior performance, cost-effectiveness, high compliance rate, and patient preference compared to other colon cancer screening options.
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...ANGLE plc
Liquid biopsy from a simple blood test is enabling personalised cancer care. The Parsortix system from ANGLE can harvest cancer cells from blood (liquid biopsy) in a non-invasive and repeatable way. This provides a new approach to obtaining cancer cells for analysis compared to traditional tumour biopsies. Key opinion leaders have evaluated the Parsortix system and found that it captures all types of cancer cells with high purity in an easy to use process, making it well suited for clinical applications in personalised cancer care.
The document discusses Troilus Gold Corp, a mining company advancing the past-producing Troilus gold and copper mine in Quebec, Canada. It provides an overview of the project's geology, history of production, existing infrastructure including roads and power lines, and growth in mineral resources. It also summarizes the company's financial information including market capitalization, institutional shareholders, and cash on hand as it works to restart mining operations at Troilus.
Eco-Stim Energy Solutions (“ESES”, “Eco-Stim”, or “Company”) is an environmentally focused oilfield service and technology company providing proprietary field management technologies, well stimulation, and completion services to oil and gas producers drilling in the rapidly expanding international unconventional shale markets. Eco-Stim’s proprietary methodology and technology offers the potential to decrease the number of stages stimulated in shale plays through a unique process that predicts high-probability production zones while confirming those production zones using the latest generation down-hole diagnostic tools. In addition, Eco-Stim offers its clients completion techniques that can dramatically reduce horsepower requirements, emissions, surface footprint, and water usage. Eco-Stim seeks to deliver well completion services with better technology, better ecology, and significantly improved economics for unconventional oil and gas producers worldwide.
EcoStim provides well stimulation, coiled tubing, and reservoir management services using proprietary technologies. It has positioned 50,000 HHP of equipment in Argentina ahead of increasing shale drilling activity. EcoStim's growth opportunity is attractive due to supply constraints in Argentina and barriers to entry that limit competitors from rapidly expanding capacity. The company has a strong customer base of major oil and gas producers operating in Argentina and is bidding on several new contracts worth over $50 million as customers finalize 2017 budgets. Argentina's shale development is following a similar path as U.S. plays and is expected to rapidly increase horizontal drilling in coming years, providing significant growth potential for EcoStim.
- The company provides well stimulation, coiled tubing, and reservoir management services using proprietary technologies that reduce environmental impact and improve economic performance.
- It has established local operations in Argentina and plans to capitalize on developing the country's large shale resources, which could reduce Argentina's need to import billions in energy annually.
- The management team has experience building profitable energy companies and exiting some for over $4.5 billion total. Major investors include Albright Capital Management, Gilder Gagnon, Bienville Capital, and Hayman Capital.
This corporate presentation discusses the company's plans to capitalize on emerging market developments and increasing demand for unconventional oil and gas solutions in Argentina. It highlights the country's large shale resources, ongoing investments by major oil companies, and an undersupplied market that leaves room for the company to expand its operations across multiple market segments. The presentation also outlines the company's leadership team and track record of success building profitable energy service platforms.
EcoStim is an emerging growth, technology-driven oilfield services company providing well stimulation, coiled tubing, and reservoir management services. It has developed proprietary technologies that reduce environmental impact and improve economic performance. The company is capitalizing on emerging market opportunities in Argentina, which has the 3rd largest shale gas reserves in the world. Argentina currently imports over $6 billion per year of oil and gas, and developing its shale resources could help reduce these imports and bolster its dollar reserves. EcoStim is well positioned for growth as Argentina's new pro-business government has made policy changes to encourage more oil and gas development.
The presentation provides an overview of Asanko Gold's operational performance and plans for 2018. Key points include:
1) Asanko produced 205,047 ounces of gold in 2017 in line with guidance. Optimization efforts have increased processing capacity to 5Mtpa.
2) Production guidance for 2018 is 200,000-220,000 ounces. The first half of 2018 will focus on waste stripping at Nkran, lowering grades and increasing costs.
3) A funding solution is being finalized to defer debt repayments beyond 2019, securing funding for an overland conveyor and development of the Esaase deposit.
4) Optimization plans aim to reduce strip ratios and costs over the expansion
Victory Energy (VYEY) Investor PresentationDerek Gradwell
Victory Energy Corporation is a public oil and gas exploration company focused on development in the Permian Basin. The company owns interests in several producing properties in the basin. Victory plans to deploy $15 million in 2014 for drilling, completions, and acquisitions to increase production and proved reserves. The goal is to achieve over 30 million barrels of proved reserves by year-end and increase revenue to over $1 million. A key focus is the recently acquired 4,050 acre Fairway project, which Victory expects can generate a 60% internal rate of return over three years of planned drilling.
The presentation discusses EcoStim's plans, strategies, and prospects, noting that some statements are forward-looking in nature. It provides an overview of EcoStim's operations in the US and Argentina, including recent contract wins that position it for growth. It highlights EcoStim's debt-free balance sheet, experienced management team, and technologies such as natural gas powered pumping units that reduce costs and emissions.
EcoStim is an oilfield services company providing well stimulation services in the US and Argentina. The presentation highlights:
1) EcoStim has secured multiple new contracts in 2017 anchoring a second crew in the US and a long-term contract in Argentina, positioning it for accelerated growth.
2) EcoStim trades at an attractive valuation compared to peers based on enterprise value per hydraulic horsepower.
3) EcoStim utilizes proprietary downhole diagnostic and predictive technologies to more efficiently target completion stages, reducing costs for customers.
- SandRidge plans to spend under $200 million in 2017 developing its assets in the Mid-Continent and North Park Basin regions.
- In the Mid-Continent, the company will appraise and develop the Meramec and Osage formations through extended reach lateral drilling in three Oklahoma counties with potential to add significant proved undeveloped reserves.
- In the North Park Basin, SandRidge aims to delineate the Niobrara oil resource through a program of exclusively extended reach laterals, with a goal of achieving per-lateral drilling and completion costs below $3 million.
This document is Oceanteam's Q4 2016 interim report. It discusses the company's financial highlights for Q4 2016, including $11.2 million in revenue and $2.8 million in EBITDA. It also summarizes key operational highlights, such as new contracts awarded, charter agreements, and expansion into new markets. Finally, it provides an overview of Oceanteam's business areas, focusing on its shipping, offshore substations, and engineering solutions divisions. The CEO message emphasizes the company's agreement with bondholders to secure new financing and its focus on offshore renewables, engineering, and new revenue streams going forward.
SandRidge Energy has built a portfolio focused on oil production growth from three key project areas: the Mississippian limestone play, NW STACK area in Oklahoma, and North Park Niobrara oil project in Colorado. The company has $554 million in liquidity and no debt. In 2017, it will continue developing the NW STACK and North Park projects with two rigs total, while high-grading its Mississippian position for cash flow. Recent well results have met or exceeded expectations at both NW STACK and North Park.
SandRidge Energy has built a portfolio focused on oil production growth from three key project areas: NW STACK, North Park Niobrara, and Mississippian. For 2017, the company plans to run two rigs in NW STACK to further delineate the Meramec and Osage formations, resume drilling at North Park Niobrara targeting multiple benches, and continue high-grading its Mississippian acreage. SandRidge has a strong balance sheet with $554 million in liquidity and no debt, positioning it to execute its development plans while generating free cash flow.
Final may invester presentation 5.30.17SandRidgeIR
The document is an investor presentation for SandRidge Energy covering operational highlights and forward looking statements. It summarizes that Sandridge has a portfolio of three oil-focused project areas with over 1,300 total 2P locations. It is focusing development on its NW STACK and North Park Niobrara projects in 2017 while harvesting its Mississippian position. Recent results in both areas have exceeded type curves with estimated ultimate recoveries of over 600 MBoe per lateral. The company had $554 million in liquidity as of early May 2017 with no debt.
SandRidge Energy has built a portfolio focused on three oil-weighted project areas: NW STACK, North Park Niobrara, and Mississippian. In 2017, the company will continue developing these areas, turning company oil production positive in late 2017. SandRidge has $563 million in liquidity and a moderate capital program focused on high-grading existing positions.
Falco Resources - March 2016 investor presentationVincent Metcalfe
Our Horne project currently holds 6.6M ozs of Gold Equivalent Resources, which 81% is in the Indicated Category. The Company is working towards completing a initial PEA in the second quarter.
In 2012, Falco Resources acquired one of Canada's most established VMS mining districts, the Rouyn Noranda Mining Camp, including the Horne Mine Complex area (birth place of Noranda in the 1920's) and 13 other former producers. Falco Resources has 100% ownership of 74,000 hectares of property, which represents 70% of the entire camp.
The document provides an overview of Antero Midstream Partners LP, including:
1) Antero Midstream is focused on organic growth through building midstream infrastructure to support production growth from its sponsor Antero Resources, one of the most active operators in the Marcellus and Utica shale plays.
2) Antero Midstream's existing assets include rich gas gathering pipelines and compression infrastructure in the Marcellus and Utica with significant planned expansion over the next year.
3) Antero Midstream has opportunities to expand across the full midstream value chain through options to acquire fresh water distribution systems and equity interests in gas pipelines.
Magma Energy Corp is a global geothermal power company that aims to build a leading pure play geothermal portfolio. It currently has 175 MW of geothermal capacity in Iceland with 80 MW of expansions underway and additional 150 MW of defined expansion plans. In the US, it has a 23 MW power plant in Nevada with expansion potential. It also recently discovered a huge 320 MW inferred resource in Chile. Magma believes its balanced portfolio approach of global exploration and operations will provide both discovery and utility returns to reduce risk and improve margins and multiples over time.
July 2016 Energy Equipment & Services: Industry Insights & HappeningsCapstone Headwaters
The latest issue of our monthly Energy Equipment & Services Report, highlighting trends in M&A, financing and capital markets for private and public companies in the energy market, is now available.
The presentation summarizes Falco Resources' Horne 5 project in Canada, which aims to develop one of the largest undeveloped gold-zinc deposits in the world. Key points include:
- The Horne 5 project could produce an average of 236,000 ounces of gold annually at an all-in sustaining cost of US$427 per ounce and has a 17-year initial mine life.
- A pre-feasibility study estimated the project would require US$680 million in development capital expenditures.
- Falco Resources' land holdings in the Rouyn-Noranda mining camp provide opportunities for additional exploration and resource expansion.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Docola has developed a healthcare communication platform that utilizes asynchronous telehealth to deliver patient education and support. Their proprietary platform currently has over 55,000 patient users and over 1,100 clinician users. Docola seeks to raise up to $500,000 through a convertible note to fund working capital, research and development, and costs associated with an upcoming IPO.
- INNO Holdings is presenting an IPO investor presentation for an initial public offering on the NASDAQ Capital Market.
- The company manufactures prefabricated steel building components and systems using proprietary technology to reduce construction costs and environmental impact.
- INNO Holdings has four initial product lines - metal studs, prefabricated housing units, modular apartment buildings, and a mobile factory system. It aims to disrupt the construction industry through standardized, sustainable construction methods.
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a biotech company developing immune monitoring and immune modulation platforms. Its AditxtScore platform can provide comprehensive immune profiles to monitor responses to pathogens, vaccines, drugs and transplants. Its Adimune platform aims to modulate the immune system to treat conditions like psoriasis, type 1 diabetes, and increase skin allograft survival. The company is working to develop, operate and commercialize these platforms. It currently generates revenue from immune monitoring tests and expects revenue from licensing deals for immune modulation programs as they advance in clinical trials towards commercialization.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
2. 2
This presentation contains statements about future events and expectations that can be
characterized as forward-looking statements, including, in particular, statements about the
Company’s plans, strategies and prospects. The use of the words “anticipate,” “estimate,”
“expect,” “may,” “project,” “believe” and similar expressions are intended to identify
forward looking statements. Although the Company believes that the plans, intentions and
expectations reflected in or suggested by such forward-looking statements are reasonable,
they do involve certain assumptions, risks, and uncertainties, and the Company cannot
assure you that those expectations will prove to have been correct. Actual results could
differ materially from those anticipated in these forward-looking statements as a result of
the factors described in this presentation. Many of these factors are beyond the
Company’s ability to control or predict. The Company cannot assure you that its future
results will meet its expectations and investors are cautioned not to place undue reliance
on any forward-looking statement made by the Company or its authorized representatives.
All subsequent written and oral forward-looking statements attributable to the Company
and persons acting on its behalf are qualified in their entirety by the cautionary
statements contained in this paragraph and elsewhere in this presentation. The Company
does not have any obligation or undertaking to disseminate any updates or revisions to
any forward-looking statement contained in this presentation or the admission document
to reflect any change in the Company’s expectations about the statement or any change in
events, conditions or circumstances on which the statement is based.
Safe Harbor Provision
3. EcoStim Investment Thesis
3
• Refinanced company establishing two market platform to balance risk;
maintain upside in Argentina
• Provide superior equipment and operations team at lowest cost
• Rely on technology to drive efficiency and cost advantage
• Focus on markets with best geology & strongest return opportunity
• Focus on natural gas development in Argentina
4. • Fresh cash injection of $17 million to repay debt,
finance capex and working capital
• Total debt of $41 million to be converted into equity at
$1.40 per share, if shareholders approve at next
meeting (June/July)
• Goal is to create a debt free company to pursue
growth in two solid and expanding markets
• Fir Tree Partners - $10 billion fund with focus on
growth & now 2nd largest shareholder; largest
shareholder following debt conversion
• Nasdaq listing a priority for Fir Tree and the Company
4
Refinanced Company In early March 2017
Description
Actual at
12/31/2016
Proforma
for Fir Tree
Transaction
Proforma
for Fir Tree
Conversion
Cash 1.8$ 15.8$ 15.8$
Debt 24.0$ 41.4$ -$
Shares Outstanding 14.5 14.5 44.1
5. Technology-driven, growth platform in solid markets
• Emerging growth, technology-driven independent oilfield service company
– Well stimulation;
– Coiled tubing; and
– Reservoir field management services
• Proprietary proven technologies and processes to:
– Reduce footprint, horsepower and capital cost;
– Emissions well below required Tier 4; Methane escape best in industry
– Use less fuel or lower cost fuel
• Initial Operation in Argentina
– Started with conventional market
– Transitioned to tight gas market in 2016
– Argentina business should move to cash flow neutral status
– 22,500 HHP remain in Argentina in 2016; more equipment to be added with
contractual commitments
• Entering US Market in Oklahoma
– One year contract in place; Start in Q2 2017
– Base established in strategic location
– Customer expanding; solid growth opportunity
Vaca Muerta
World’s 3rd largest
shale resource basin
5
6. EcoStim Rolling Stock – Equipment Distribution
Moving from 10,000 HHP in 2015 to over 100,000 HHP in 2017
6
OklahomaArgentina
Data VanHydration
BlenderBlender
Data Van
Data Van
Hydration
BlenderBlender
Blender
SandKing
Crew #1 - 16 pumps (35,000 HHP)
Crew #2 & Redundancy -24 pumps (54,000 HHP)
Lease Unit
Lease Unit
Lease Unit
Lease Unit
Blender
- Owned & Ready to Operate
- To be Upgraded
- To be purchased
- Lease option in place
HydrationDataVan
26 Tractors & 10 Light Trucks
Sand & Chemical Handling Equipmnet
Palmero Unit
Flex Crew - 14 pumps (31,500 HHP)
Hydration
SandKingSandKing
TPUs
7. 7
Evercore Research shows that when our equipment is put to work,
we should be able to more than triple the value of the Company
8. Seasoned leadership team with local
and international experience
Bjarte Bruheim
Chairman and Founder
J. Chris Boswell
President, CEO and
Founder
Alexander Nickolatos
Chief Financial Officer and
Assistant Secretary
Carlos A. Fernandez
Sr. VP, Corp. Development
General Mgr., Latin America
Relevant Experience
• 28 years experience in the oilfield service industry
• 15+ years experience in finance and accounting
• 30+ years international management experience
• 35+ years senior management experience in Latin America
Bobby Chapman
Chief Operating Officer
• 35+ years senior management oilfield experience
Miguel Di Vincenzo
VP, Sales & Technology
• 28 years oilfield services experience in Latin America
8
Barry Ekstrand
Sr. VP, Operations
• 35+ years senior management oilfield experience
9. • Co-founded by Bjarte Bruheim in
1991; served as President until 2001
• Chris Boswell CFO from 1995-2002;
directed >$3 billion in growth capital
• Grew from 2 ships to 33% share of
the marine seismic market by 1998
• Now has 16 marine seismic vessels,
with 33 offices in 25 countries
• Developed in 1995 by Bjarte Bruheim,
Chris Boswell and others utilizing
PGS’ seismic library as seed capital
• Initially funded by Warburg Pincus
• Completed $116 million IPO in 1999
• Acquired by Norsk Hydro ASA (now
Statoil ASA) for $2.45 billion in 2005
• Deepwater exploration venture initially
capitalized by Bjarte Bruheim and
Warburg Pincus
• Acquired certain electromagnetic
technologies from Statoil ASA in 2004
• Completed IPO in 2007 valuing the
company at ~$1.6 billion
• Bjarte Bruheim named Executive
Chairman of financially troubled
seismic equipment designer in 2002
• Successfully arranged new investor
capital to help turn around company
• Sold to Rolls-Royce in 2009 for
approximately $200 million
• Co-founded by Bjarte Bruheim in
2009 as an E&P vehicle to utilize
EMGS technology to de-risk offshore
targets
• Sold to Tullow Oil in 2012 for up to
$672 million total consideration
• Norwegian marine seismic venture co-
founded by Bjarte Bruheim in 2005
• Listed on Oslo Stock Exchange in 2007
• Signed contracts for construction of 6
advanced 12-streamer 3D vessels
• Acquired by Schlumberger in 2007 for
$838 million in cash consideration
• Co-founded by Bobby Chapman in
2005 with backing from Soros and ESS
• Grew to 6 crews and 130,000 HHP by
the second half of 2007
– Contracts in place for 3 additional
crews at 56,000 HHP
• Sold to Trican Well Service in 2007 for
$256 million
• In 2009, Chris Boswell was hired as
CFO to re-set strategy and divest
assets for a distressed silicon valley
backed oilfield technology company
• Mr. Boswell and Carlos Fernandez
successfully farmed 5 blocks in
Neuquén province of Argentina
• Arranged $60 million in expansion
capital from new investors in 2011,
including Microsoft founder Bill Gates
and Energy Capital Group
Management team has consistent track record of building
profitable energy & energy service platforms
Five exits valued at +$4.5 billion; Three ongoing entities valued at $2+ billion 9
10. 10
Establishing two strong positions in high growth markets
with long term contracts
Argentina’s Neuquén Province – Tight
Gas and Vaca Muerta shale Oklahoma’s Mississippian/Stack/Scoop Plays
11. 11
Contract signed with well established operator in Oklahoma
• Contract is for one year beginning on “readiness” date (estimated Q2 of 2017)
• Investment is relatively light to achieve readiness; much of the equipment is
available or has been secured
• ESES to execute all well stimulation stages performed monthly (estimated to be 35-
40 stages until second rig is added) utilizing approximately 25% of capacity
• Customer expects to add second rig in second half of 2017; doubling stage count
• Work will not require sand and only light chemical package; little working capital
• In discussion with other operators in area to secure additional wells/stages
• Area is becoming more active
12. Expansion to the US starts in North Central Oklahoma to position
EcoStim to service the growing regional market
- ESES base of operation
12
13. 13
Midstates - Woods – 1
Comanche - Major – 1
Chesapeake – Major – 1
Kirkpatrick – Major 1
Tapstone - Woodward – 1
Devon – Woodward - 1
Sandridge – Woodward – 1
PPP Petroleum – Ellis – 1
Logan – Red Bluff Resources – 1
White Star – Payne - 1
Dewey – 6
Blaine – 19
Kingfisher – 17
Canadian - 8
Custer – 5
Washita – 0
Caddo – 0
Grady – 14
Beckham - 5
Operators & Rigs as of January 2017; OK rig count up by 60%
since March 2016
• Devon
• Chesapeake
• Continental
• Cimarex
• Marathon
• Newfield
• Linn Energy
• Gastar
• Oklahoma Energy
• Carrera Energy
• Chaparral
• Hinkle
• Council Oaks Resources
• Super Heaters, LLC
Major Operators in Stack/Scoop
14. 14
OK rig count up further in March 2017; New base in close proximity to
Blaine/Kingfisher counties
15. Argentina’s growth opportunity is unique
1. Geology – Resource produces
economic hydrocarbons
2. Pace of activity – Sufficient wells to
maintain good equipment
utilization
3. Demand for hydrocarbons –
Production consumed locally or
export potential
4. Infrastructure – Roads, housing,
fuel, pipelines and support services
5. Local knowledge – Feet on the
ground; local network
6. Business risk – Regulations, taxes,
security, culture, ethics, etc.
Source: EIA and Accenture.
15
Key Selection Criteria For International Shale
Market Opportunities
16. Source: WoodMackenzie /
YPF
Shale Oil Benchmarking
Summary from YPF’s Recent Earnings Webcast
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
Wolfcamp Vaca Muerta Bone Springs Eagle Ford Bakken
Vaca Muerta Well Productivity Compared To Best in USA
EUR / Foot of Lateral Length
16
17. What has changed in Argentina?
New pro-business, free markets President
Natural Gas prices set at $6.00-7.50 through 2021
Currency controls removed
New trade agreement with US & rejoins IMF
New deal between government, labor unions, and energy
companies expected to double investment
Shell signs new exploration deal with YPF
Tecpetrol commits $2.3B to Vaca Muerta and Tight Gas
17
18. Drilling efficiency gains – Eagle Ford vs Vaca Muerta
0
20
40
60
80
100
120
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Drilling days per horizontal well
Eagle Ford Vaca Muerta
18
Source: Management Estimates & YPF Public Data
19. Mature oil producing country with strong
customer base
E&P Companies Operating in Argentina
Source: Management research
19
21. Review of past business and new contract
opportunities for EcoStim
2015 Customers
New Customers - 2016
New Contracts – 2017
And Partners
21
22. Argentina market oversupplied in 2016 due to rig count reduction.
Rigs starting back to work, prices improving; barriers to entry remain
22
Barriers to Entry:
• Importation of new stimulation equipment is still challenging
• Any new equipment into country must be negotiated with at least 3 agencies (Ministry of Industry, Department
of Trade, and Customs Office)
• Matching agreements need to be negotiated with local vendors
• Government still favors protectionist policies to support local industry
• Repatriation of dollars has been difficult historically; still scares some competitors
23. Neuquén Offices and Operational Base
2 OFFICES IN NEUQUEN AND 1 OFFICE IN BA
ACTUAL YARD AT THE PIN NEUQUEN AND FUTURE YARD IN PLOTTIER
23
27. EXECUTION - Technology well suited to reduce cost and
environmental impact
Only pumping unit in the world capable of:
– running on 100% natural gas
– can run on multiple fuel sources including natural gas, CNG, LNG and Diesel
– delivering emissions 65% below EPA Tier 4 requirements
– delivering 4500 HHP from a single trailer with engines weighing ~ 800 pounds each
– Proprietary control system modified & enhanced with automated functions
27
CNG tube trailer –
2200 psi
Heater to avoid freeze
up during
decompression
Gas conditioning skid
to remove liquids
4500 HHP on one
trailer
28. Multiple Natural Gas Fueling OptionsMultiple Natural Gas Fueling Options
Traditional EcoStim
First Frac Operation with TPU in Argentina
EXECUTION - Technologies Integration
28
29. “You can’t manage what you don’t measure”
• Leverages fiber-optic technology and predictive modeling (how many stages don’t actually produce hydrocarbons?)
• Enables Eco-Stim to efficiently predict stimulation effectiveness and understand the shale in real-time
1. Predict
3. Measure
4. Evaluate
Prediction
Proprietary process to efficiently
predict “sweet spots” in shale plays
Stimulate all planned stages
as designed
Downhole technologies to determine
which stages are actually producing
Compare prediction of
sweet spots to actual
production
“Learn” best producing areas of the
formation in a given area and
incorporate information into next
geophysical prediction
5. Update
Model
2. Execute
Predict, Execute, Measure, Evaluate, Re-Predict
Eco-Stim conducts its horizontal stimulation services within a systematic methodology
29
30. Example of “sweet spot” PREDICTION; largely based on the
identification of micro-fracture swarms or “natural fracturing”
Technology used primarily in high cost regions
30 Ft
Flare
7610
5 Ft
Flare
7970
5 Ft
Flare
8630
5 Ft
Flare
8742
3 Ft
Flare
9659
4 Ft
Flare
10480
4 Ft
Flare
11305
Targeted Sweet Spots
-
+
• Using proprietary technology
for accurate well placement
and stimulation stage planning
• Maps produced in less than
three weeks at minimal cost
• Over 350 shale projects
completed in U.S. shale plays
• Over 25 projects completed in
Argentina
Curvature Attributes
• Flares correlate with Geo-
Predict sweet spot mapping –
confirming the effectiveness of
Geo-Predict’s methodology
Mud logs on this horizontal well show flare markers that confirm predictive fracture maps
30
31. MEASURE & EVALUATE - Confirmation of producing zones…..
(It is generally accepted that only one of three stages produce hydrocarbons)
… Derived from Fiber Optic Acoustic Signatures
TIME
Gas Production from zone 6
Gas + Water Production
from zone 8
9 7 6 5 4 3 2 18
31
32. UPDATE MODEL & CALIBRATE - Target completion stages based
on technology & empirical data
32 Stages @ $100k / Stage = $3.2 Million
16 Stages @ $100k / Stage = $1.6 Million
32
33. EcoStim Investment Thesis
33
• Refinanced company establishing two market platform to balance risk;
maintain upside in Argentina
• Provide superior equipment and operations team at lowest cost
• Rely on technology to drive efficiency and cost advantage
• Focus on markets with best geology & strongest return opportunity
• Focus on natural gas development in Argentina